Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial
Author:
Affiliation:
1. Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College; Beijing China
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference31 articles.
1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer.,2010
2. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer;Estevez;Clin Cancer Res.,2004
3. Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial;Pacilio;Br J Cancer.,2006
4. Capecitabine plus docetaxel combination therapy;Verma;Cancer.,2005
5. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?;Leonard;Ann Oncol.,2006
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The prognosis and risk factors for capecitabine maintenance treatment in metastatic breast cancer: a retrospective comparative cohort study;Annals of Translational Medicine;2022-09
2. Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer;British Journal of Cancer;2021-09-03
3. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer;Cochrane Database of Systematic Reviews;2021-05-26
4. Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis;Annals of Translational Medicine;2021-01
5. Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China;International Journal of Cancer;2020-07-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3